Immutep Limited (IMM.AX)
Develops cancer immunotherapy drugs that boost the immune system's ability to fight tumors.
0.05+0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-81.9%
The outlook
IMM.AX trades near its 52-week lows with analyst sentiment mixed at "Hold." The stock sits well below both its 50- and 200-day moving averages, signaling a downtrend, though the average analyst price target sits roughly 120% above the current price.
What’s behind the score
Analyst consensusHold — 2.8 avg of 3 analysts
Price trendBelow its 50- & 200-day averages
52-week range4% of the way from its 52-week low to high
Price targetAvg target +120% vs current price
Analyst price target
~12-month · 3 analysts0.10average target+119.9% vs now
Now 0.05
Low 0.04High 0.20
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$69.3M
52-wk high
0.47
52-wk low
0.03
50-day avg
0.05
200-day avg
0.21
Trailing P/E
—